Iztam-2.25/Iztam-4.5

Iztam-2.25/Iztam-4.5

piperacillin + tazobactam

Manufacturer:

Penmix

Distributor:

Bellus Life Solutions
Concise Prescribing Info
Contents
Iztam-2.25 Piperacillin Na 2 g, tazobactam Na 250 mg. Iztam-4.5 Piperacillin Na 4 g, tazobactam Na 500 mg
Indications/Uses
Appendicitis (complicated by rupture or abscess) & peritonitis; uncomplicated & complicated skin & skin structure infections including cellulitis, cutaneous abscesses & ischemic/diabetic foot infections; postpartum endometritis or pelvic inflammatory diseases; community-acquired pneumonia (moderate severity only); nosocomial pneumonia (moderate to severe).
Dosage/Direction for Use
IV infusion over 30 min. Adult 3.375 g every 6 hr (piperacillin 12 g/tazobactam 1.5 g) for 7-10 days. Nosocomial pneumonia Initial presumptive treatment: 4.5 g every 6 hr + aminoglycoside (piperacillin 16 g/tazobactam 2 g) for 7-14 days. All indications (except nosocomial pneumonia) Renal impairment CrCl >40 mL/min 3.375 g every 6 hr, 20-40 mL/min 2.25 g every 6 hr, <20 mL/min 2.25 g every 8 hr. Hemodialysis & CAPD 2.25 g every 12 hr. Nosocomial pneumonia Renal impairment CrCl >40 mL/min 4.5 g every 6 hr, 20-40 mL/min 3.375 g every 6 hr, <20 mL/min 2.25 g every 6 hr. Hemodialysis & CAPD 2.25 g every 8 hr. Appendicitis &/or peritonitis Childn >40 kg Adult dose, ≥9 mth & <40 kg Piperacillin 100 mg/tazobactam 12.5 mg every 8 hr, 2-9 mth Piperacillin 80 mg/tazobactam 10 mg every 8 hr.
Contraindications
Hypersensitivity to penicillins, cephalosporins or β-lactamase inhibitors.
Special Precautions
Neuromuscular excitability or convulsions in higher doses. Clostridium difficile associated diarrhea. Risk of development of drug-resistant bacteria. Monitor closely if patient develops skin rash & discontinue if lesions progress. Perform periodic assessment of hematopoietic function especially w/ prolonged therapy ie, ≥21 days; electrolyte determinations in patients w/ low K reserves. Concomitant use w/ vancomycin. Patient requiring restricted salt intake. Delayed recovery of renal function in critically ill patients. Pregnancy & lactation.
Adverse Reactions
Diarrhea, constipation, nausea, vomiting, dyspepsia, abdominal pain; fever, inj site reaction, rigors; anaphylaxis; candidiasis, pseudomembranous colitis; hypoglycemia; myalgia, arthralgia; headache; insomnia; rash (including maculopapular, bullous & urticarial), pruritus, purpura; phlebitis, thrombophlebitis, hypotension, flushing; epistaxis.
Drug Interactions
May inactivate aminoglycosides. Prolongs t½ w/ probenecid. Increased incidence of acute kidney injury w/ vancomycin. Prolongation of neuromuscular blockade of vecuronium. Reduced clearance of methotrexate. High doses of heparin, oral anticoagulants or other drugs that may affect blood coagulation system or thrombocyte function.
MIMS Class
ATC Classification
J01CR05 - piperacillin and beta-lactamase inhibitor ; Belongs to the class of penicillin combinations, including beta-lactamase inhibitors. Used in the systemic treatment of infections.
Presentation/Packing
Form
Iztam-4.5 powd for inj for IV infusion 4.5 g
Packing/Price
50 mL x 10 × 1's
Form
Iztam-2.25 powd for inj for IV infusion 2.25 g
Packing/Price
20 mL x 10 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in